Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0061 absolute bioavailability, pharmacokinetics, and tolerability study in healthy volunteers
NL-OMON40925Active, not recruiting
- Sponsor
- Ablynx
- Start
- Mar 2014
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of vobarilizumab in rheumatoid arthritis (RA) (5 arms), sponsored by Ablynx. Primary endpoint: Pharmacokinetics of single subcutaneous and intravenous ALX-0061. Started Mar 2014; status: active, not recruiting.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40925.